Skip to main content

Table 1 The nine GHRL / GHSR polymorphisms examined in the meta-analysis, the number of studies performed in cancer samples and sample sizes

From: Associations between ghrelin and ghrelin receptor polymorphisms and cancer in Caucasian populations: a meta-analysis

    N studies    
  Polymorphism References Cancer type   Number of  
  BC CRC EC NHL Total Cases Controls Total
1 GHRL 696217 [10-14],[23] 3 1 1 1 6 3,601 6,101 9,702
2 GHRL 4684677 [10-12],[23] 2 1 1 0 4 2,888 4,938 7,826
3 GHRL 27647 [11],[12],[23] 2 2 0 0 4 2,512 3,709 6,221
4 GHRL 26802 [11],[12],[23] 2 1 0 0 3 1,958 2,994 4,952
5 GHRL 2075356 [11],[12],[23] 2 1 0 0 3 1,941 2,972 4,913
6 GHRL 35684 [11],[13],[23] 1 1 0 1 3 2,144 3,480 5,624
7 GHRL 35683 [12],[23] 1 2 0 0 3 1,864 1,949 3,813
8 GHSR 495225 [11],[14],[23] 2 1 0 0 3 2,350 3,370 5,720
9 GHSR 572169 [11],[14],[23] 2 1 0 0 3 2,378 3,414 5,792
  1. Studies have examined ghrelin gene (GHRL) or ghrelin receptor gene (GHSR) polymorphisms in breast cancer (BC); colorectal cancer (CRC); esophageal cancer (EC); and Non-Hodgkin’s Lymphoma (NHL) [10-14],[23].
  2. SNPs in bold were examined in more detail in the current study.